Background: A large body of evidence suggests that nҀ3 fatty acids from fish prevent fatal heart disease. They may be an effective and safe alternative to drug treatment for reducing the risk of arrhythmia and sudden cardiac death. Objective: We investigated the effect of nҀ3 fatty acids on heart rate and premature ventricular complexes (PVCs), a common form of arrhythmia that may trigger arrhythmias that are more lifethreatening. Design: Patients (n ҃ 84) with ͧ1440 PVCs/24 h in a previous Holter recording were randomly assigned to receive 1.5 g/d of either nҀ3 fatty acids or placebo. Two 24-h Holter recordings were made at baseline, and 2 were made after an intervention of Ȃ14 wk.
INTRODUCTION
Clinical trials show a beneficial effect of moderate intakes (Ȃ1 g/d) of nҀ3 fatty acids on mortality and sudden cardiac death. This effect is seen within a few months after the beginning of treatment, but there is little or no effect on nonfatal events (1, 2) . In addition, observational studies show strong inverse relations of fish consumption or blood concentrations of nҀ3 fatty acids with the incidence of fatal coronary artery disease and sudden cardiac death, but not with nonfatal heart disease (3) (4) (5) (6) . In addition, experimental studies have indicated that nҀ3 fatty acids increase the arrhythmia threshold and effectively prevent ventricular fibrillation in animal and in vitro models (7) . Thus, results from different types of studies suggest that nҀ3 fatty acids have an immediate effect on arrhythmia rather than a slow effect via regression of atherosclerosis.
Frequent premature ventricular complexes (PVCs) are independent predictors of sudden cardiac death and mortality in patients with a history of myocardial infarction (MI), significant left ventricular (LV) dysfunction, or both (8 -10) . Moreover, in middle-aged men without prior symptoms of cardiovascular disease, frequent PVCs during exercise predicted long-term risk of cardiovascular death (11) . However, there are no data that ambient PVCs are predictive of an adverse prognosis in patients without structural heart disease. n-3 Fatty acids might intervene in the occurrence of PVCs by slowing down the spontaneous beating rate or by prolonging the refractory period (7) . PVCs are a common form of arrhythmia that are themselves innocent but that may trigger more serious arrhythmic events, such as ventricular tachycardia or ventricular fibrillation (12) . Thus a reduction in PVCs results in fewer triggers and may in that way decrease the risk of more serious arrhythmic events. It should be noted, however, that effects on PVCs do not necessarily parallel effects on endpoints. In the Cardiac Arrhythmia Suppression Trial (CAST; 13), encainide and flecainide did reduce the number of PVCs but increased rather than decreased mortality. In contrast, it is conceivable that nҀ3 fatty acids prevent PVCs and at the same time reduce fatal arrhythmias and mortality. Therefore, if effective, nҀ3 fatty acids may be a safe alternative to drug treatment of arrhythmias.
A study by Sellmayer et al (14) suggested that nҀ3 fatty acids can reduce the incidence of PVC in patients with spontaneous PVCs. The mean Ȁ SD number of PVCs decreased from 6937 Ȁ 5192 at the beginning of the intervention to 3591 Ȁ 3884 after 16 wk of intervention in the fish-oil group, whereas, in the placebo group, the number decreased from 6306 Ȁ 3363 to 4728 Ȁ 3320. Although the effects were impressive, this potentially important finding urgently required confirmation. In addition, nҀ3 fatty acids may reduce heart rate and in this way reduce the risk of sudden death (15) (16) (17) . Therefore, the aim of the current study was to investigate the effect of nҀ3 fatty acids on the incidence of PVCs and on heart rate in patients with frequent PVCs. Demonstration of an effect on PVCs would provide clues as to possible underlying mechanisms and may also add to the evidence that nҀ3 fatty acids prevent fatal heart disease by preventing serious ventricular arrhythmia.
SUBJECTS AND METHODS

Subjects
We defined frequent PVCs as an average of ͧ1/min, or 1440/24 h. On that basis, cardiologists recruited and enrolled patients aged ͧ18 y who had ͧ1440 PVCs/24 h in a Holter recording made 6 mo before. Patients who used antiarrhythmic drugs other than ␤-blockers were excluded, as were those with known left ventricular dysfunction, sustained tachycardia, symptomatic ischemia, hemodynamically relevant valvular defects, or other cardiac diseases related to arrhythmia. Patients who had used any supplemental nҀ3 fatty acids during the previous 3 mo were also excluded.
Ninety-two patients who met the inclusion criteria were randomly assigned to receive n-3 fatty acids or placebo; 84 of the 92 successfully completed the study. One patient was excluded because of the use of prescribed antiarrhythmic medication, and one patient died during the study. Four patients dropped out for personal reasons, one because of perceived side effects, and one because of admission to the hospital.
The study protocol was approved by the Medical Ethics Committee of Wageningen University. Patients gave their written informed consent after the study protocol had been explained to them.
Design and treatment
This placebo-controlled, double-blind study with parallel design was conducted in 3 hospitals in the Netherlands. Patients were randomly assigned in blocks of 2 units, stratified for history of MI. Patients received a daily 3.5-g dose of either fish oil or placebo oil (high-oleic acid sunflower oil; Loders Croklaan, Wormerveer, Netherlands) during the intervention period of 14 Ȁ 1 wk. The oils were administered daily in 7 soft gelatin capsules each containing 500 mg oil and 1.5 mg tocopherol as an antioxidant (Banner Pharmacaps Europe BV, Tilburg, Netherlands). The daily dose of fish oil provided Ȃ700 mg eicosapentaenoic acid (EPA; 20:5n-3), 560 mg docosahexaenoic acid (DHA; 22:6n-3), and 260 mg of other nҀ3 fatty acids. The placebo capsules contained mainly oleic acid (18:1n-9).
Data collection
Twenty-four-hour Holter recordings were made with SEER MC digital recorders (GE Medical Systems Information Technologies, Milwaukee). We averaged the results of 2 Holter recordings made at baseline and those of 2 Holter recordings made at the end of the study (in both cases, the 2 recordings were made 1 wk apart) to reduce the large variation in the occurrence of PVCs.
Data on demographics, medical history, and cardiac medication were collected at baseline and recorded on the case report form. Intakes of energy, fatty acids, cholesterol, and alcohol were estimated once during the intervention by a telephoneadministered 24-h dietary recall. In addition, to assess and monitor their fish intake, patients were interviewed at baseline and at the end of the intervention with the use of a questionnaire on the frequency of fish consumption. Body mass index and blood pressure were monitored during the study. Patients recorded the intake of capsules in a diary. We took nonfasting blood samples a few days before the beginning of the treatment and during the last week of the intervention. Serum cholesteryl fatty acids were analyzed as described previously (18) .
Holter analysis
The 24-h Holter recordings were analyzed with a Marquette Series 8000 Holter analyzer (GE Medical Systems Information Technologies) by an experienced Holter technician who was unaware of the treatments. Initially, all beats were automatically categorized into different classes on the basis of their morphology. The technician ensured that the classes were correctly identified. In addition, for each class containing 10 PVCs, all beats within that class were laid on top of each other (by layering the different electrocardiograms digitally on the screen) to check for possible misclassification of non-PVCs, and all outliers were removed. The frequency of PVCs was calculated by dividing the number of PVCs by the total time that the signal was of sufficiently high quality for analysis. The mean heart rate was calculated as the total number of normal beats in sinus rhythm (3 consecutive normal beats) divided by the recording duration after correction for noise and episodes of nonsinus rhythm.
Statistical analysis
A pretrial power calculation showed that 40 subjects per group would be sufficient to detect a significant difference (P 0.05) in the change in numbers of PVCs in response to the intervention between the fish-oil and placebo groups with a power of 80%, if the real population effect exceeded 25%. The primary outcome of the study was the change in number of PVCs during the treatment. Differences in the changes in numbers of PVCs and heart rate between the fish-oil and placebo groups were analyzed by using Student's t test. Analysis of a subgroup of patients with and without prior MI was planned a priori and included in the protocol. Significance was set at P 0.05. Statistical analyses were performed by using SPSS for WINDOWS software (version 10.0.5; SPSS, Chicago).
RESULTS
Differences in baseline characteristics between the fish-oil and the placebo groups were not significant ( Table 1) . Compliance was reflected by a mean change in the amount of EPA (in g/100 g total fatty acids) in serum cholesteryl esters during intervention of 181% in the fish-oil group and Ҁ2% in the placebo group. For DHA, the change was 49% in the fish-oil group and Ҁ5% in the placebo group ( Table 2) . Two patients in the fish-oil group and 2 in the placebo group stopped taking the capsules before the study was finished because they experienced side effects that they believed were due to the treatment: skin rashes, gastrointestinal complaints, and nausea (1 patient in each group). Analyses were performed including the data from these 4 patients, but results did not change when they were excluded.
The effect of treatment on the number of PVCs/24 h did not differ significantly between the fish-oil and placebo groups. The n-3 FATTY ACIDS, PVCs, AND HEART RATE number decreased by a mean of 867 (6%) more in the fish-oil group than in the placebo group (95% CI: Ҁ3187, 1453), as shown in Table 3 . In the small subgroup of 22 patients with prior MI, the mean response was an increase of 2717 (ѿ23%) more in the fish-oil group than in the placebo group (95% CI: Ҁ2254, 7689) ( Table 3 ). In the subgroup of 62 patients without prior MI, the mean response was a decrease of 2129 (Ҁ22%) more in the fish-oil group than in the placebo group (95% CI: Ҁ4764, 507) ( Table 3) .
Twenty-four-hour mean heart rate decreased by an average of 2.1 beats/min more in the fish-oil group than in the placebo group, and this difference was significant (95% CI: Ҁ3.9, Ҁ0.3) ( Table 3) . Heart rate results in the subgroups with and without prior MI were very similar to those in the entire cohort (Table 3) . Blood pressure and body mass index were not affected by treatment (data not shown).
Background dietary intake did not differ significantly between the 2 treatment groups. The fish-oil group consumed 33% of energy as fat, 0.6% of energy (1.4 g/d) as total nҀ3 fatty acids (mostly ALA), 4% of energy as alcohol, and 24 mg cholesterol/ MJ. In the placebo group, the corresponding values were 33%, 0.5% (1.1 g/d), 5%, and 28 mg cholesterol/MJ. Fish intake did not differ significantly between the treatment groups and did not change significantly during the intervention.
DISCUSSION
Daily intake of 1.5 g nҀ3 fatty acids for Ȃ14 wk did not significantly affect the number of PVCs in patients who had been experiencing frequent PVCs. In a clinical setting, an individual positive response to treatment can be defined as a reduction by 70% in the number of PVCs in a particular patient. In the current study, only 3 patients in the fish-oil group and 7 patients in the placebo group showed such a reduction. These results indicate that nҀ3 fatty acids from fish are not very effective in the treatment of PVCs in this study.
Sellmayer et al (14) tested the effects of the intake of 2.4 g nҀ3 fatty acids/d in 68 patients with a minimum of 2000 spontaneous PVCs/24 h. They found a reduction of 70% in the number of PVCs in 15 patients (44%) after fish-oil intake and in 5 patients (15%) after placebo intake. Recently, a reduction in PVCs was seen after the intake for 6 mo of 1 g nҀ3 fatty acids/d in 33 patients with low numbers of PVCs (214 Ȁ 76/24 h at baseline) (19) . In contrast, a significant effect of nҀ3 fatty acids on the number of PVCs was absent in 3 other small studies (20 -22) . Even if we combine the results of all studies, it is still questionable whether nҀ3 fatty acids can indeed reduce PVCs.
Protective effects of nҀ3 fatty acids on hard endpoints in clinical trials have been found only for post-MI patients (2, 23, 24) . In contrast, no effects or even adverse effects were found in a trial in 3114 angina patients who were advised to eat 2 portions of fatty fish each week or to ingest 3 g fish oil/d (25) . It is hard to explain these adverse results, but it may be suggested that the cardioprotective effect of nҀ3 fatty acids is restricted to patients with earlier MI. n-3 Fatty acids may interact with structural abnormalities in hearts that have undergone MI and thus prevent fatal electrical events. Our population, overall, was low-risk: we excluded patients with LV dysfunction from the study, and only 25% of the subjects had a history of MI. When we restricted our analysis to this subgroup of 11 subjects per treatment, we saw a nonsignificant increase in PVCs in patients given nҀ3 fatty acids. Although power was limited for subgroup analyses, we have no indications that the mechanism behind the possible antiarrhythmic effect of nҀ3 fatty acids in these patients involves PVCs as potential arrhythmic triggers. However, the effects could be different in a higher-risk population, eg, patients with LV dysfunction.
n-3 Fatty acids significantly (P ҃ 0.022) decreased heart rate by 2.1 beats/min. An observational study reported an inverse association between nҀ3 fatty acids and heart rate (26). Moreover, some intervention studies reported that nҀ3 fatty acids or DHA alone decrease heart rate in different patient populations by 2.2 to 3.5 beats/min (15) (16) (17) . Increased heart rate is an independent risk factor for sudden death but not for fatal MI in middleaged men free of known cardiovascular disease (27) (28) (29) (30) . On the basis of the work of Jouven et al (27) , a decrease of 2.1 beats/min in heart rate would predict a risk reduction for sudden cardiac death of 6%. It can be speculated that nҀ3 fatty acids affect heart rate through stabilizing electrical activity of isolated cardiac myocytes by elevating the action potential threshold and prolonging relative refractory time (7) . These actions may affect electrical stimulation of the sinus node resulting in a lower heart rate. However, nҀ3 fatty acids also may affect sympathetic and 1 PVCs, premature ventricular complexes; ALA, ␣-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid. There were no significant differences between groups (t test).
x Ȁ SD (all such values).
3 ALA accounts for Ȃ20% of the n-3 fatty acid intake from fish. 1 All values are x Ȁ SD. EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid. The EPA and DHA results in the fish-oil and placebo groups were significantly different, P ͨ 0.0001 (t test).
2 The fish-oil group received 3.5 g fish oil (1.5 g n-3 fatty acids); the placebo group received 3.5 g high-oleic acid sunflower oil.
3 Serum fatty acid results are missing for 1 subject in the placebo group.
parasympathetic control of heart rate by virtue of their interaction with the adrenergic system (31) . Baseline characteristics of the fish-oil and placebo groups were somewhat similar but not identical. The most important difference (although not a significant difference) is that the number of PVCs at screening was somewhat higher in the fish-oil group than in the placebo group. However, this difference would be expected to result in a larger, rather than smaller, decrease in the number of PVCs, because of regression to the mean or because higher numbers give more room for a decrease. In addition, we did find an effect of nҀ3 fatty acids on heart rate, despite differences in baseline characteristics between groups. Altogether, it seems unlikely that the lack of a distinct effect on the number of PVCs can be explained by baseline differences between the fish-oil and placebo groups.
The evidence from different types of studies suggesting that nҀ3 fatty acids may reduce serious ventricular arrhythmia risk justifies further research on this potentially protective mode of action (7) . It is hoped that definitive answers will come from current long-term trials of nҀ3 fatty acids and arrhythmia incidence in high-risk patients with an implantable cardioverter defibrillator (ICD) (32) . We are aware of 3 such trials, of which 1 recently reported preliminary results. This study in 200 subjects with an ICD showed a trend, over a 2-y follow-up, toward increased rather than decreased recurrence of ventricular arrhythmias in patients who received nҀ3 fatty acids during the study (33) . The results of the other 2 ICD trials are required, before definitive conclusions can be drawn. In addition, in a pilot study, the immediate effect of nҀ3 fatty acids was assessed in patients with an ICD (34) . Sustained ventricular tachycardia was not induced in 5 of 7 patients. This antiarrhythmic effect should be confirmed in a larger, randomized, placebo-controlled trial.
In the current randomized, double-blind study, dietary nҀ3 fatty acids significantly decreased heart rate by 2.1 beat/min, which predicts a lower risk of sudden death (27) . However, nҀ3 fatty acids are apparently not very effective in the treatment of PVCs. This makes it less likely that the presumed effect of nҀ3 fatty acids on the risk of sudden cardiac death is mediated by a reduction in the frequency of triggers of arrhythmia. Nevertheless, further exploration of this hypothesis is warranted, and trials on life-threatening arrhythmia and mortality are needed to support dietary recommendations.
TABLE 3
Number of premature ventricular complexes (PVCs) per 24 h and heart rate at the beginning and the end of the intervention period, the response to the intervention, and the difference in response between the fish-oil and placebo groups for all patients and for patients with and without prior myocardial infarction (MI) 
